Adam W R, Meagher E J, Barter C E
Clin Exp Hypertens A. 1982;4(8):1419-28. doi: 10.3109/10641968209060799.
The effects on lung function of labetalol (a combined alpha and beta adrenergic receptor blocker) and three beta adrenergic receptor blockers (propranolol, atenolol, metoprolol) have been assessed in patients with chronic airflow obstruction using a double-blind trial. With the dosages used, all drugs produced an equivalent fall of blood pressure. Propranolol was the only drug that significantly increased airways obstruction (FEV1, specific airways resistance). Following salbutamol, labetalol was associated with a significantly greater improvement of airflow than either propranolol or metoprolol. On these acute studies, the order of preference for beta blocking drugs in management of hypertension in patients with obstructive airways disease, would be labetalol, (atenolol) or (metoprolol) and then propranolol.
已通过双盲试验评估了拉贝洛尔(一种α和β肾上腺素能受体联合阻滞剂)及三种β肾上腺素能受体阻滞剂(普萘洛尔、阿替洛尔、美托洛尔)对慢性气流阻塞患者肺功能的影响。使用所采用的剂量时,所有药物均使血压同等程度下降。普萘洛尔是唯一显著增加气道阻塞(第一秒用力呼气量、比气道阻力)的药物。使用沙丁胺醇后,拉贝洛尔使气流改善程度显著大于普萘洛尔或美托洛尔。基于这些急性研究,对于阻塞性气道疾病患者,β受体阻滞剂在高血压治疗中的首选顺序为拉贝洛尔、(阿替洛尔)或(美托洛尔),然后是普萘洛尔。